Filgotinib is an oral, selective JAK1 inhibitor combining a high level of clinical efficacy and rapid onset of action with a differentiated safety profile in RA patients. While people of any age can be affected by RA, the disease is common in the elderly. Age-related processes like a decline in enzyme activity or glomerular filtration rate (GFR) may have an impact on drug metabolism and pharmacokinetics (PK). Given that metabolism followed by renal excretion is the main route of elimination for filgotinib and its active metabolite, the impact of age as well as renal impairment on PK was studied. 

Influence of age and renal impairment on pharmacokinetics of filgotinib (GLPG0634), a selective JAK1 inhibitor

Florence Namour1, Liesbeth Fagard2, Annegret Van der Aa2, Pille Harrison2 and Chantal Tasset2

1 Galapagos SASU, Romainville, France; 2 Galapagos NV, Mechelen, Belgium

Introduction
Filgotinib is an oral, selective JAK1 inhibitor combining a high level of clinical efficacy and rapid onset of action with a differentiated safety profile in RA patients. While people of any age can be affected by RA, the disease is common in the elderly. Age-related processes like a decline in enzyme activity or glomerular filtration rate (GFR) may have an impact on drug metabolism and pharmacokinetics (PK). Given that metabolism followed by renal excretion is the main route of elimination for filgotinib and its active metabolite, the impact of age as well as renal impairment on PK was studied.

Study design
In an open-label study, two groups (N=10 per group) of healthy elderly subjects (40-50 years and ≥ 75 years) and one group of younger healthy subjects (40-50 years) received once daily oral doses of 100 mg filgotinib for 10 days. Subjects were body-weight-matched across each age group.

Limited effect of Age

Influence of age and renal impairment on pharmacokinetics of filgotinib (GLPG0634), a selective JAK1 inhibitor

Florence Namour1, Liesbeth Fagard2, Annegret Van der Aa2, Pille Harrison2 and Chantal Tasset2

1 Galapagos SASU, Romainville, France; 2 Galapagos NV, Mechelen, Belgium

Introduction
Filgotinib is an oral, selective JAK1 inhibitor combining a high level of clinical efficacy and rapid onset of action with a differentiated safety profile in RA patients. While people of any age can be affected by RA, the disease is common in the elderly. Age-related processes like a decline in enzyme activity or glomerular filtration rate (GFR) may have an impact on drug metabolism and pharmacokinetics (PK). Given that metabolism followed by renal excretion is the main route of elimination for filgotinib and its active metabolite, the impact of age as well as renal impairment on PK was studied.

Study design
In an open-label study, two groups (N=10 per group) of healthy elderly subjects (40-50 years and ≥ 75 years) and one group of younger healthy subjects (40-50 years) received once daily oral doses of 100 mg filgotinib for 10 days. Subjects were body-weight-matched across each age group.

Limited effect of Age

Influence of age and renal impairment on pharmacokinetics of filgotinib (GLPG0634), a selective JAK1 inhibitor

Florence Namour1, Liesbeth Fagard2, Annegret Van der Aa2, Pille Harrison2 and Chantal Tasset2

1 Galapagos SASU, Romainville, France; 2 Galapagos NV, Mechelen, Belgium

Introduction
Filgotinib is an oral, selective JAK1 inhibitor combining a high level of clinical efficacy and rapid onset of action with a differentiated safety profile in RA patients. While people of any age can be affected by RA, the disease is common in the elderly. Age-related processes like a decline in enzyme activity or glomerular filtration rate (GFR) may have an impact on drug metabolism and pharmacokinetics (PK). Given that metabolism followed by renal excretion is the main route of elimination for filgotinib and its active metabolite, the impact of age as well as renal impairment on PK was studied.

Study design
In an open-label study, two groups (N=10 per group) of healthy elderly subjects (40-50 years and ≥ 75 years) and one group of younger healthy subjects (40-50 years) received once daily oral doses of 100 mg filgotinib for 10 days. Subjects were body-weight-matched across each age group.